Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis

By sjmartinez • April 27, 2023

Spiera R, Kuwana M, Khanna D, Hummers L, Frech TM, Stevens W, Matucci-Cerinic M, Kafaja S, Distler O, Jun JB, Levy Y, Leszcyzński P, Gordon J, Steen V, Lee EB, Jankowski T, Litinsky I, Chung L, Hsu V, Mayes M, Sandorfi N, Simms RW, Finzel S, de Vries-Bouwstra J, Constantine S, Dgetluck N, Dinh Q, Bloom BJ, Furst DE, White B, Denton CP; RESOLVE-1 Study Group. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2023 Apr 26. doi: 10.1002/art.42510. Epub ahead of print. PMID: 37098795.

Tags: Publications, Rheumatology

Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset

Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K, Hayashi H, Sakai K, Enatsu S, Frimodt-Møller[...]

Artificial Intelligence in Patch Testing: Comprehensive Review of Current Applications and Future Prospects in Dermatology

Tang HS, Ebriani J, Yan MJ, Wongvibulsin S, Farshchian M. Artificial Intelligence in Patch Testing: Comprehensive Review of Current Applications and Future Prospects in Dermatology.[...]

Author Correction: Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in mice

Özcan E, Yu KB, Dinh L, Lum GR, Lau K, Hsu J, Arino M, Paramo J, Lopez-Romero A, Hsiao EY. Author Correction: Dietary fiber content[...]